Indegene Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Indegene has been growing earnings at an average annual rate of 25.3%, while the Life Sciences industry saw earnings growing at 20.2% annually. Revenues have been growing at an average rate of 9.7% per year. Indegene's return on equity is 15.8%, and it has net margins of 13.8%.
Belangrijke informatie
25.3%
Groei van de winst
23.4%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 11.2% |
| Inkomstengroei | 9.7% |
| Rendement op eigen vermogen | 15.8% |
| Nettomarge | 13.8% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Indegene geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 27,097 | 3,730 | 17,322 | 0 |
| 30 Jun 24 | 26,586 | 3,560 | 16,912 | 0 |
| 31 Mar 24 | 25,896 | 3,367 | 16,560 | 0 |
| 31 Dec 23 | 25,489 | 2,907 | 16,452 | 0 |
| 30 Jun 23 | 23,927 | 2,487 | 15,593 | 0 |
| 31 Mar 23 | 23,061 | 2,661 | 14,688 | 0 |
| 31 Mar 22 | 16,646 | 1,648 | 10,222 | 0 |
| 31 Mar 21 | 9,806 | 1,857 | 5,403 | 0 |
| 31 Mar 20 | 6,436 | 558 | 3,738 | 0 |
Kwaliteitswinsten: INDGN has high quality earnings.
Groeiende winstmarge: INDGN's current net profit margins (13.8%) are higher than last year (10.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: INDGN's earnings have grown significantly by 25.3% per year over the past 5 years.
Versnelling van de groei: INDGN's earnings growth over the past year (38.3%) exceeds its 5-year average (25.3% per year).
Winst versus industrie: INDGN earnings growth over the past year (38.3%) exceeded the Life Sciences industry 13.3%.
Rendement op eigen vermogen
Hoge ROE: INDGN's Return on Equity (15.8%) is considered low.